I have seen couple of times that co. comes up with CR after presentations or road show and that is the only bit I am afraid of, otherwise it is a sure value at this price.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%